Practice Management

ESCRS 2026: Why surgeons should be willing to use what they prescribe to patients

ByMfazo Hove, MBChB, MD, FRCOphth, CertLRS,Martin David Harp

September 22nd 2026

Hove stresses surgeons who prescribe premium lenses or laser surgery to patients should be willing to have those same treatments themselves when needed.

Mfazo Hove, MD, shares his own experience with a trifocal IOL, two and a half years after cataract surgery

ByMfazo Hove, MBChB, MD, FRCOphth, CertLRS,Martin David Harp

September 16th 2026

Hove explains how his own cataract surgery has changed the way he counsels patients about glare, halos, and near vision.

The case for private practice fellowships

ByEsteban Peralta, MD,Andrew Yazji, MD,Robert J. Weinstock, MD

August 7th 2026

Private practice fellowships sharpen cataract and refractive skills with high volume, new tech, and hands-on practice management mentorship.

ASRS 2026: Nearly 40% of patients with wet AMD go untreated for 180 days within the first year

ByAndrew Moshfeghi, MD, MBA, FASRS,Martin David Harp

July 20th 2026

New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year, and treatment gaps are linked to worse long-term vision.

Practice Management

ESCRS 2026: Why surgeons should be willing to use what they prescribe to patients

Mfazo Hove, MD, shares his own experience with a trifocal IOL, two and a half years after cataract surgery

The case for private practice fellowships

ASRS 2026: Nearly 40% of patients with wet AMD go untreated for 180 days within the first year

Trending on Eye Care Network - Ophthalmology Times

Brepocitinib meets all Phase 3 end points in noninfectious uveitis

Matching artificial tears to dry eye phenotype: a Q&A with Omur Ucakhan, MD

Demodex blepharitis: Diagnosis, treatment response, and recurrence

Myopia control using spectacle lenses with highly aspherical lenslets

CHMP recommends ranibizumab biosimilar Fovlussea for retinal disease